SLC1A5 and neoplasm: Similar results can be observed when recombinant Gal-4 treatment inhibits tumor growth by decreasing the phosphorylation of SLC1A5 (a glutamine transporter) in colon cancer cells [83], and Kazenmaier et al. identified that Gal-12 can bind to SLC1A5 to reduce glutamine uptake in colon cancer cells [81].